Aaron Gal
Stock Analyst at Bernstein
(0.60)
# 3,223
Out of 4,667 analysts
22
Total ratings
33.33%
Success rate
-6.78%
Average return
Main Sectors:
Stocks Rated by Aaron Gal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Initiates: Outperform | $105 | $88.63 | +18.47% | 6 | Oct 17, 2024 | |
| ABBV AbbVie | Initiates: Market Perform | $203 | $167.76 | +21.01% | 2 | Oct 17, 2024 | |
| AMGN Amgen | Initiates: Outperform | $380 | $287.87 | +32.00% | 3 | Oct 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,125 | $743.35 | +51.34% | 3 | Mar 11, 2024 | |
| BIIB Biogen | Upgrades: Outperform | $500 | $156.00 | +220.51% | 6 | Jun 11, 2021 | |
| VTRS Viatris | Initiates: Market Perform | $21 | $13.13 | +59.94% | 1 | Dec 14, 2020 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $17.03 | - | 1 | Aug 4, 2017 |
Gilead Sciences
Oct 17, 2024
Initiates: Outperform
Price Target: $105
Current: $88.63
Upside: +18.47%
AbbVie
Oct 17, 2024
Initiates: Market Perform
Price Target: $203
Current: $167.76
Upside: +21.01%
Amgen
Oct 17, 2024
Initiates: Outperform
Price Target: $380
Current: $287.87
Upside: +32.00%
Regeneron Pharmaceuticals
Mar 11, 2024
Initiates: Outperform
Price Target: $1,125
Current: $743.35
Upside: +51.34%
Biogen
Jun 11, 2021
Upgrades: Outperform
Price Target: $500
Current: $156.00
Upside: +220.51%
Viatris
Dec 14, 2020
Initiates: Market Perform
Price Target: $21
Current: $13.13
Upside: +59.94%
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.03
Upside: -